Current status and future directions of immunotherapy for solid tumors
Immunotherapy has revolutionized clinical treatment of solid tumors,becoming a core strategy for the treatment of solid tumors. Currently approved immunotherapy strategies for solid tumors include PD-1 antibodies,CTLA-4 antibodies,bispecific antibodies,TCR-T cells,and TIL. These approaches primarily exert antitumor effects by activating T-cell-mediated immune responses or directly supplementing tumor-reactive T cells. However,restrained by inhibitory factors within the tumor microenvironment,the therapeutic outcomes of these strategies remain suboptimal. Based on the cancer-immunity cycle theory,this article provides a systematic review of approved immunotherapy strategies,early-stage clinical trials,and emerging immunotherapy approaches. It also offers insights into the future directions of immunotherapy targeting T cells and other cell populations beyond T cells.
cancer immunitycancer immunotherapyimmune checkpoint inhibitorstumor microenvironmentadoptive cell therapy
万方数据
维普
